Comparison of serum CA72-4, CEA, TPA, CA19-9 and CA125 levels in gastric cancer patients and correlation with recurrence

被引:4
|
作者
Lai, IR
Lee, WJ
Huang, MT
Lin, HH
机构
[1] En Chu Kong Hosp, Dept Surg, Taipei, Taiwan
[2] En Chu Kong Hosp, Dept Pathol, Taipei, Taiwan
[3] Natl Taiwan Univ Hosp, Dept Surg, Taipei, Taiwan
关键词
CA72-4; gastric cancer;
D O I
暂无
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Background/Aims: Serum tumor markers were investigated as prognostic factors for recurrence in patients with gastric cancers. Methodology: Preoperative serum levels of CEA, CA72-4, CA19-9, TPA and CA125 were sampled in 196 patients with gastric cancers undergoing curative surgery. The results were compared with the clinical recurrence and various clinicopathological factors. Results: CA72-4; CEA, CA19-9, TPA and CA125 had sensitivities of 16.4%, 31.4%, 16.1%, 31.6%, and 6%, respectively. Sensitivity of two combinations was as high as 56.5 %. Seventy-seven patients (39.9%) had clinical recurrence in the follow-up periods. For those with preoperatively elevated serum tumor markers, 38% (12/32) had CA72-4, 42% (13/31) had CA19-9, 48% (29/60) and had CEA, 54% (6/11) had CA125, and,62% (37/61) had TPA, and, remained, disease-free. Univariate analysis showed that TNM staging, Tumor size, Borrmann classification of tumor growth, and preoperative serum CA72-4 level, were correlated with recurrence of disease. Multivariate analysis showed that independent prognostic factor of recurrence was TNM staking (P=0.0007). Conclusions: Preoperative serum CA12-4 level is correlated with staging of disease, but is not an independent predictor for clinical recurrence of disease in patients with gastric cancers that undergo surgery.
引用
收藏
页码:1157 / 1160
页数:4
相关论文
共 50 条
  • [1] Differences and correlation of serum CEA, CA19-9 and CA72-4 in gastric cancer
    Yu, Junxiu
    Zhang, Shuguang
    Zhao, Bingbo
    MOLECULAR AND CLINICAL ONCOLOGY, 2016, 4 (03) : 441 - 449
  • [2] Evaluation of serum CEA, CA19-9 and CA72-4 levels in patients with gastric cancer
    Nishi, M
    Miyamoto, H
    Takagi, H
    Sasaki, K
    Tashiro, S
    3RD INTERNATIONAL GASTRIC CANCER CONGRESS, 1999, : 475 - 478
  • [3] CLINICAL EVALUATION OF CEA, CA125, CA19-9 AND CA72-4 IN GASTRIC CANCER PATIENTS WITH ADJUVANT CHEMOTHERAPY
    Abbas, M.
    Fransis, S.
    Naveed, M.
    Mohammad, I. S.
    Tengli, C.
    Nepal, A.
    Thao, D. T.
    Meiqi, S.
    Dingding, C.
    VALUE IN HEALTH, 2017, 20 (09) : A732 - A732
  • [4] Clinical evaluation of CEA, CA19-9, CA72-4 and CA125 in gastric cancer patients with neoadjuvant chemotherapy
    Zhipeng Sun
    Nengwei Zhang
    World Journal of Surgical Oncology, 12
  • [5] Clinical evaluation of CEA, CA19-9, CA72-4 and CA125 in gastric cancer patients with neoadjuvant chemotherapy
    Sun, Zhipeng
    Zhang, Nengwei
    WORLD JOURNAL OF SURGICAL ONCOLOGY, 2014, 12
  • [6] Clinical value of CA125, CA19-9, CEA, CA72-4, and TPA in borderline ovarian tumor
    Tamakoshi, K
    Kikkawa, F
    Shibata, K
    Tomoda, K
    Obata, NH
    Wakahara, F
    Tokuhashi, Y
    Ishikawa, H
    Kawai, M
    Tomoda, Y
    GYNECOLOGIC ONCOLOGY, 1996, 62 (01) : 67 - 72
  • [7] CA72-4 combined with CEA, CA125 and CA19-9 improves the sensitivity for the early diagnosis of gastric cancer
    Yang, Ai-Ping
    Liu, Jun
    Lei, He-Yue
    Zhang, Qun-Wei
    Zhao, Long
    Yang, Guo-Hui
    CLINICA CHIMICA ACTA, 2014, 437 : 183 - 186
  • [8] Increased serum CA125 II, but not CEA?CA19-9?AFP or CA72-4 in colon cancer compared to rectal cancer
    Liu, T.
    Li, X.
    Liu, D.
    Liu, S.
    Dong, M.
    BRITISH JOURNAL OF BIOMEDICAL SCIENCE, 2021, 78 (04) : 218 - 220
  • [9] An Alternative Method for Screening Gastric Cancer Based on Serum Levels of CEA, CA19-9, and CA72-4
    Yu J.
    Zheng W.
    Journal of Gastrointestinal Cancer, 2018, 49 (1) : 57 - 62
  • [10] Clinical significance and diagnostic value of serum CEA, CA19-9 and CA72-4 in patients with gastric cancer
    Liang, Yao
    Wang, Wei
    Fang, Cheng
    Raj, Seeruttun Sharvesh
    Hu, Wan-Ming
    Li, Qi-Wen
    Zhou, Zhi-Wei
    ONCOTARGET, 2016, 7 (31) : 49565 - 49573